Clinical trial
Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in…
NCT00383591 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00383591 |
|---|---|
| Title | Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years |
| Official title | A Phase III, Clinical Trial Comparing the Persistence of GSK Biologicals New Adjuvanted Hepatitis B Vaccine to a Double Dose of Engerix™-B at Months 24, 30, 36, in Pre-haemodialysis/Haemodialysis Patients (≥15 Years of Age) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Biological |
| Interventions | Hepatitis B adjuvanted vaccine, Engerix-B |
| Enrollment | 120 |
| Start date | Mar 1, 2002 |
| Completion | Jan 1, 2004 |
| First posted | Oct 3, 2006 |
| Last update posted | Mar 23, 2017 |
| Countries | Czechia, Malaysia, Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: